APRE חוב כולל להון Aprea

A team of experienced biopharmaceuticals manages Aprea Therapeutics (APRE) with an emphasis on transparency and the mitigation of FDA risks, while adhering to basic environmental standards for chemical disposal. This chart of current market quotes illustrates a total debt-to-equity ratio of 0.00. The business focuses on restoring tumor suppressor functions, paving the way for a monopoly in ovarian cancer treatment and high profitability.

This ratio determines the degree of financial leverage by comparing total liabilities to net assets to assess bankruptcy risk. An analysis of total debt relative to equity confirms that Aprea Therapeutics (APRE) operates on investment infusions, as the absence of commercial products leaves the company dependent on external financing until the completion of clinical trials.